

Molecule	Originator brand	Indication	Strengths	Admini- stration	Form	Main sec- tor ¹	Type of dossier	Dossier availability	DP ²	Expected launch ³
Caspofungin	Cancidas® by Merck	Antifungal, systemic	50 mg, 70 mg	Parenteral	Powder for solu- tion for infusion	Hospital	EU-CTD	Available	Expired	Commercial
Anidulafungin	Ecalta® by Pfizer	Antifungal, systemic	100 mg	Parenteral	Powder for solu- tion for infusion	Hospital	EU-CTD	Available	Expired	Commercial
Micafungin	Mycamine® by Astellas	Antifungal, systemic	50 mg, 100 mg	Parenteral	Powder for solu- tion for infusion	Hospital	EU-CTD	Available	Expired	Commercial
Tigecyclin	Tygacil® by Pfizer	Antibacterial, systemic	50 mg	Parenteral	Powder for solu- tion for infusion	Hospital	EU-CTD	Available	Expired	Commercial / 03.2026 (FDF)
Rivaroxaban	Xarelto® by Bayer	Anticoagulant	2.5 mg, 10 mg, 15 mg, 20 mg	Oral	Film-coated tablets	Retail	EU-CTD	Available	Expired	04.2024 / 01.2026
Ticagrelor	Brilique® by AstraZeneca	Anticoagulant	60 mg, 90 mg	Oral	Film-coated tablets	Retail	EU-CTD	Available	Expired	06.2025 (PE ³)
Tafamidis Meglumine	Vyndaquel® by Pfizer	Amyloidosis	20 mg	Oral	Soft-gel capsules	Mixed	EU-CTD	Q3'2023	Expired	11.2026
Tafamidis	Vyndaquel® by Pfizer	Amyloidosis	61 mg	Oral	Soft-gel capsules	Mixed	EU-CTD	Q1'2024	02.2030	2031
Macitentan	Opsumit® by Actelion	Pulmonary hypertension	10 mg	Oral	Film-coated tablets	Mixed	EU-CTD	Q4'2023	12.2023	12.2026
Isavuconazole	Cresemba® by Basilea	Antimycotic	100 mg	Oral	Hard capsules	Hospital	EU-CTD	Q3'2025	10.2025	2026
			200 mg	Parenteral	Powder for solu- tion for infusion	Hospital	EU-CTD	Q1'2025		
Carfilzomib	Kyprolis® by Amgen	Multiple mye- loma	10 mg, 30 mg, 60 mg	Parenteral	Powder for solu- tion for infusion	Hospital	EU-CTD	Q3'2025	11.2025	08.2030
Osimertinib	Tagrisso® by AstraZeneca	Non-small cell lung cancer	40 mg, 80 mg	Oral	Film-coated tablets	Mixed	EU-CTD	Q1'2026	02.2024	07.2032
Baricitinib	Olumiant® by Eli Lilly	Rheumatoid arthritis	2 mg, 4 mg	Oral	Film-coated tablets	Mixed	EU-CTD	Q4'2026	02.2025	02.2032

¹ Main sector is based on average IMS sales distribution by SU in Europe.

² DP = Data protection expiry in Europe (EU)

³ Expected launch date applies for market entry of generic products in major European countries. Please check specific patent situation in any particular country of interest.

³ Paediatric extension granted.